Presenting on the above topic is Dr Helen Han, VP & Head, Global Preclinical Devt, APAC & Global BD, Johnson & Johnson Pharmaceuticals R&D, China. She will be speaking at Pharma Trials World Asia 2012, part of a series of conferences at the 5th Annual BioPharma Asia Convention 2012.
Dr Helen Han Hsu is presently Vice President, Head of Drug Safety Sciences, Asia Pacific and Global Head of Business Development at Janssen Pharmaceutical Research and Development, a member of Johnson and Johnson Companies. Her 13 years tenure with Johnson and Johnson also included Senior Director, Head of Toxicology/Pathology/Laboratory Animal Medicine at Raritan NJ, and Director of Preclinical Drug Development, Skin Research Center, Johnson and Johnson Consumer Products Worldwide. Her past appointments included Director of Pathology at Novartis Pharmaceuticals Corporation, and Research Pathologist at Ciba-Geigy, Wyeth Laboratories and National Center for Toxicological Research. Helen is a diplomate of the American College of Veterinary Pathologists. She received her residency training and Ph.D. from Department of Pathology, School of Veterinary Medicine, Cornell University. At the National Taiwan University in Taipei, she earned her D.V.M.. Prior to her Asia Pacific assignment, she was an active member and subcommittee team lead of the American PhRMA Preclincial Leader Steering Committee. In that role, she managed current and emerging issues in pharmaceutical industry. She is also a member of several other professional societies, amongst those include the American College of Veterinary Pathologists, Society of Toxicological Pathologists, Society of Toxicology, American College of Toxicology, and American Veterinary Medicine Association. Helen won Johnson & Johnson?s Standards of Leadership Award in 1999, 2001, and 2007; and in 2004, she was recognized with a Tribute to Women and Industry (TWIN) Award, which acknowledged her significant contributions to pharmaceutical industry. In the fields of Toxicology and Veterinary Pathology, Helen has published more than 40 scientific papers and one book chapter. She has also given more than 50 presentations in professional society meetings.
Dr Helen Han will be sharing on the following:
Developing a suitable business model for your preclinical drug development in Asia
1. Evaluating the challenges of existing preclinical models in the transformation of the pharma industry
2. Leveraging on the uniqueness of the preclinical landscape in Asia to fast-track drug development
3. Case study: Building a successful preclinical model in Asia
She will also be participating in the below panel discussion:
Panel Discussion: Assessing Asia's competitiveness and growth opportunities in conducting preclinical trials
1. Evaluating changes in the preclinical scene in Asia in the past five years
2. Challenges in preserving the value of preclinical studies for sustainability in Asia's emerging markets
3. Developing the future direction in preclinical and R&D policy strategies for the potential increase in preclinical trials